{"disease":{"id":"acute-myeloid-leukaemia","name":"acute myeloid leukaemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06790680","title":"GITMO AML/MDS-Relapse Registry Study","phase":"","overall_status":"COMPLETED","enrollment_count":859,"lead_sponsor_name":"Gruppo Italiano Trapianto di Midollo Osseo","has_results":false},{"nct_id":"NCT06345365","title":"MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":154,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT03873311","title":"Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":114,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT05086315","title":"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":101,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06793410","title":"Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT06783478","title":"NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT07264010","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":87,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07155226","title":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07244367","title":"Maintenance Venetoclax in AML Fit Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT06621212","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT02333058","title":"Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"medac GmbH","has_results":false},{"nct_id":"NCT07379528","title":"Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06947044","title":"Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Donald Arnold","has_results":false},{"nct_id":"NCT07249476","title":"Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04326764","title":"Panobinostat Maintenance After HSCT fo High-risk AML and MDS","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Goethe University","has_results":false},{"nct_id":"NCT03217838","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06848270","title":"Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Universidade do Porto","has_results":false},{"nct_id":"NCT01028716","title":"Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":46,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02979366","title":"Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03672695","title":"Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03957915","title":"Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT06326697","title":"Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Hikma Pharmaceuticals LLC","has_results":false},{"nct_id":"NCT07148180","title":"A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"Jacqueline Garcia, MD","has_results":false},{"nct_id":"NCT06928909","title":"Leukemia Adapted Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT06326021","title":"Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07036250","title":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","has_results":false},{"nct_id":"NCT04629443","title":"Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":true},{"nct_id":"NCT07518654","title":"Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Michel Duval","has_results":false},{"nct_id":"NCT07203885","title":"AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Harvard Medical School (HMS and HSDM)","has_results":false},{"nct_id":"NCT05942599","title":"Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT05712278","title":"A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04106076","title":"Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Cellectis S.A.","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}